FDA Dextrose 10% Injection Shortage: Distributor Impact

FDA Reports Current Shortage of Dextrose 10% Injection: Distribution Impact for Wholesale Drug Distributors

The FDA added dextrose 10% injection to its active drug shortage list on March 21, 2025, with multiple manufacturers reporting supply interruptions affecting hospital and specialty pharmacy channels. Wholesale drug distributors holding active pharmaceutical licenses should immediately assess allocation protocols and customer communication procedures under 21 CFR 203.32 and applicable state pharmacy board requirements.

Regulatory Context

The FDA maintains the Drug Shortages Database under authority of the FDA Safety and Innovation Act (FDASIA), which requires manufacturers to notify the agency of anticipated interruptions or discontinuances for medically necessary drugs. Dextrose 10% injection qualifies as medically necessary under the agency's shortage criteria due to its use in total parenteral nutrition (TPN) compounding and critical care protocols.

Wholesale drug distributors do not have a statutory obligation to report shortages to FDA, but state pharmacy board regulations in 23 jurisdictions require licensed distributors to maintain records documenting allocation decisions when supply constraints affect customer fulfillment. The National Association of Boards of Pharmacy (NABP) Model Rules for the Licensure of Wholesale Distributors include recommended recordkeeping practices for shortage management, though these are not binding unless adopted by individual state boards.

Under 21 CFR 203.32, wholesale distributors must establish written policies and procedures for handling, storage, and distribution of prescription drugs. Shortage conditions trigger scrutiny of these procedures during state board inspections, particularly around documentation of allocation methodologies and customer notification timelines.

Current Shortage Status

FDA's March 21, 2025 shortage entry for dextrose 10% injection lists the following manufacturers with reported supply constraints:

• Baxter Healthcare: Manufacturing delay at North Carolina facility. Estimated recovery: June 2025.
• B. Braun Medical: Increased demand exceeding production capacity. No recovery date provided.
• Fresenius Kabi: Raw material supply interruption. Estimated recovery: May 2025.
• Hospira (Pfizer): Active supply, but allocation in place due to competitor shortages.

The FDA drug shortage database lists dextrose 10% injection in 250mL, 500mL, and 1000mL flexible bag presentations as currently constrained. The 5% dextrose concentration remains available without reported shortages. The agency has not issued a temporary importation authorization or compounding guidance as of this publication date.

The shortage affects hospital inpatient pharmacies, specialty infusion providers, and long-term care facilities that rely on dextrose 10% for parenteral nutrition protocols. Wholesale distributors serving these customer segments report order volume increases of 40-60% as facilities attempt to build inventory ahead of anticipated supply gaps.

Distribution Impact for Wholesale Operators

Wholesale drug distributors should implement or review the following operational protocols in response to the dextrose 10% injection shortage:

Allocation methodology documentation: State pharmacy boards in California, Florida, New York, Ohio, and Texas have issued guidance requiring distributors to document allocation decisions during shortage periods. Written policies must specify allocation criteria (e.g., historical order volume, patient acuity, alternative product availability) and demonstrate non-discriminatory application across customer accounts.

Customer notification requirements: Distributors holding unfilled orders for dextrose 10% injection should notify affected customers within 24-48 hours of order placement, per recommended practices in NABP's Model Rules. Notification should include estimated ship date, available alternative concentrations, and manufacturer recovery timelines when known.

Inventory recordkeeping: Maintain electronic or paper records of all dextrose 10% injection receipts, allocations, and shipments during the shortage period. State board inspectors may request these records during routine compliance audits to verify adherence to written allocation policies.

Alternative product guidance: Distributors should coordinate with pharmacy customers to identify clinically appropriate alternatives, including dextrose 5% injection with potassium supplementation or concentrated dextrose for custom TPN compounding. Product interchange decisions are the responsibility of the dispensing pharmacist and prescriber, not the distributor.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 licensed wholesale drug distributors across 51 U.S. jurisdictions. Of these entities, 1,234 hold active FDA establishment registration — a baseline requirement for distributing prescription drugs, including dextrose injection products. The average compliance score across the directory is 51/100, placing the majority of tracked distributors in the "Fair" tier (919 entities), which reflects verified state licensure and FDA registration but limited visibility into NABP accreditation or recall history.

During drug shortage periods, compliance posture becomes operationally relevant beyond routine audits. Distributors with documented allocation policies, robust recordkeeping systems, and established customer communication protocols — signals reflected in higher compliance scores — are better positioned to demonstrate state board compliance if allocation decisions are scrutinized. Only 63 entities in the ColdChainCheck directory hold NABP accreditation (formerly VAWD), which includes standards for written policies and procedures under the NABP Model Rules that align with state board expectations during shortages.

The 73 entities with FDA recalls or warning letters on record may face heightened scrutiny during shortage conditions. State pharmacy boards reviewing allocation complaints often cross-reference an entity's compliance history when evaluating whether allocation decisions were applied consistently and non-discriminatorily.

Practical Steps for QA and Compliance Teams

• Verify distributor compliance status before placing shortage-period orders: Use the ColdChainCheck directory to confirm your current dextrose suppliers hold active state licenses in your jurisdiction and maintain FDA registration. Entities with compliance scores below 40/100 may lack verified licensure in all states where they claim to operate.

• Document alternative supplier qualification: If your primary distributor implements allocation, identify backup suppliers using the directory's state filter and FDA registration status. Qualify alternative distributors using their publicly available compliance data before executing purchase orders under time pressure.

• Review allocation notification timelines: Compare your distributor's notification practices against state board requirements. California Business and Professions Code Section 4169 and Ohio Administrative Code 4729-6-03 both reference "prompt notification" standards — 24-48 hours is recommended industry practice.

• Monitor manufacturer recovery timelines: ColdChainCheck does not track manufacturer-level shortage data, but the FDA Drug Shortage Database provides manufacturer-specific recovery estimates. Cross-reference this data with your distributor's allocation communications to assess forecast accuracy.

For related coverage of wholesale distributor obligations during supply chain disruptions, see ColdChainCheck's Compliance Guides section, which includes state-specific licensure requirements and NABP accreditation standards.

Disclaimer: This article provides informational content based on publicly available FDA data and applicable regulations as of the publication date. It does not constitute legal or regulatory advice. Entities should consult qualified legal counsel and relevant regulatory authorities to ensure compliance with all applicable requirements.